Access
To read this story in full you will need to login or make a payment (see right).
News
Nature 447, 512-513 (31 May 2007) | doi:10.1038/447512a; Published online 30 May 2007
Open Innovation Challenges
-
Efficient Chromosome Doubling: Plant Cell Division
The Seeker is looking for an efficient chromosome doubling method in plants and in particular, metho...
-
Protect Enzyme from In Planta Degradation
A proposal for stable expression of an enzyme in corn seed is desired.
- More Challenges
- Powered by:
nature jobs
Postdoctoral Fellowship
- Lovelace Respiratory Research Institute
- Albuquerque, New Mexico
Principal Scientist - In Vivo Pain Biologist
- GlaxoSmithKline
- Harlow, Essex United Kingdom
Weighing up the evidence
Heidi Ledford
Abstract
A meta-analysis of clinical trials for the diabetes drug Avandia has hinted at possible cardiovascular risks; but how clear is the study, and how should meta-analyses be viewed against clinical trials?
The day after concerns about Avandia hit the news, the emergency room at New York City's Bellevue Hospital was even more hectic than usual. Patients with diabetes filed in and asked to discontinue their medication while the phone rang with calls from other Avandia users.
To read this story in full you will need to login or make a payment (see right).
